Sarepta Therapeutics has announced that Chris Garabedian has resigned as President, Chief Executive Officer (CEO), and as a member of the Board of the company, effective immediately.
Edward Kaye, MD, the company’s Chief Medical Officer (CMO) will act as interim CEO.
Patient perspectives generate specific outcome objectives, what they are willing to do to achieve them, the risks they are willing to bear, and the costs they are willing to pay. The same could be said about payers.
Merck announced that they are stopping their head to head comparative phase 3 study in advanced melanoma early since they met their primary endpoint ahead of schedule. In the competitive world of big pharma, that is considered a slam dunk.